This space is reserved for stepone to introduce himself.

Stepone's Latest Comments

Hi Paul, Thanks for the response. I'm fine with Stocko pushing more stuff subscriber only. They are in good company with the FT, Times, etc. To be honest although I enjoy reading SCVR and the comments, I don't generally buy small caps these days, so I'll not be subscribing, although I will miss reading it. All the Best, StepOne

Got an email from stockopedia. All editorial comment, including SCVR, going subscriber only from 12th April. Maybe we can blame Brexit?

So SCVR is going subscriber only. Mark Brumby also introduced a subscriber version of his daily email. Are these signs of the top of the market ? I think maybe yes..

One thing to notice is that up to now Bioventix have always beaten the forecasts. So, for year ending June 2018, the forecasts started at £6m revenue, then were increased to 6.3m and then 6.9m, and actual turnover came in at £7.9m (plus 700k backdated royalties). Turnover growth this latest half year was 24% and that's without any significant contribution from Troponin sales, which they…

Vitamin D for year ending June 2018 was £3.4m from total sales of £7.9m, so, yes, definitely significant.

stepone Followers

stepone has 1 follower including:

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis